Implementation program for advanced pancreatic cancer care
Nationwide Implementation Program for Optimal Multidisciplinary Management and Resection of Locally Advanced Pancreatic Cancer (PREOPANC-4)
This program is testing new ways to improve treatment and survival rates for people with locally advanced pancreatic cancer in the Netherlands by using the best practices from around the world.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 223 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Amsterdam, North Holland) |
| Trial ID | NCT05524090 on ClinicalTrials.gov |
What this trial studies
This program aims to implement international best practices for the care of locally advanced pancreatic cancer (LAPC) in the Netherlands from 2021 to 2030. It includes a multidisciplinary training initiative involving leading international expert centers to enhance patient selection and treatment outcomes. The focus is on improving the resection rates and five-year survival for LAPC patients through a structured approach to chemotherapy and surgical techniques. The program will evaluate the effectiveness of these practices in a real-world setting.
Who should consider this trial
Good fit: Ideal candidates for this program are adults aged 18 and older with pathology-confirmed locally advanced pancreatic cancer who have shown non-progressive disease after at least four months of systemic chemotherapy.
Not a fit: Patients with metastatic pancreatic cancer or those with extensive arterial involvement may not benefit from this program.
Why it matters
Potential benefit: If successful, this program could significantly improve survival rates for patients with locally advanced pancreatic cancer by increasing the number of patients eligible for surgery.
How similar studies have performed: Other studies have shown success with similar multidisciplinary approaches in improving outcomes for pancreatic cancer, indicating that this implementation program is building on established practices.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years or older * Pathology-confirmed (LAPC)\* * CT-based non-progressive disease (RECIST criteria) after at least 4 months of systemic chemotherapy (\[m\]FOLFIRINOX / gemcitabine-nab-paclitaxel). Exclusion Criteria: * Metastatic pancreatic cancer prior to induction chemotherapy. * According to the Dutch Pancreatic Cancer Group (DPCG) definition: \>90 degrees arterial tumor involvement (i.e. superior mesenteric artery, celiac axis, and/or hepatic artery) and/or portovenous involvement of either \>270 degrees or occlusion.
Where this trial is running
Amsterdam, North Holland
- Amsterdam UMC, locatie AMC — Amsterdam, North Holland, Netherlands (Recruiting)
Study contacts
- Principal investigator: Marc G Besselink, MD, MSc, PhD — Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Study coordinator: Thomas F Stoop, MD
- Email: t.f.stoop@amsterdamUMC.nl
- Phone: +316 547 555 11
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.